Amgen Inc. took a step forward in its efforts to make its Kyprolis cancer therapy a standard treatment for many multiple myeloma patients, saying the drug performed better than older rival Velcade in a study.

Amgen, of Thousand Oaks, Calif., said patients taking Kyprolis as part of their drug regimen in the 929-subject study lived 18.7 months without their multiple myeloma worsening, about twice as long as patients taking the...